NCT00358956View on ClinicalTrials.gov

A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

May 31, 2014

Conditions
Thyroid Cancer
Interventions
DRUG

ZD6474 (vandetanib)

100 mg once daily oral tablet

Trial Locations (9)

Unknown

Research Site, Little Rock

Research Site, Boston

Research Site, St Leonards

Research Site, Sherbrooke

Research Site, Pisa

Research Site, Utrecht

Research Site, Bucharest

Research Site, Madrid

Research Site, Basel

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00358956 - A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer | Biotech Hunter | Biotech Hunter